Drugs / QLS2309
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07173595 | Dec 2025 → Dec 2027 expected | refractory hematologic cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS2309 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07173595 ↗ |
| Route | Intravenous | “intravenous infusion” NCT07173595 ↗ |